Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

One-lung ventilation to treat hepatic dome lesion – a further step towards minimally invasive surgery: a case report

  • 1, 2Email author,
  • 1,
  • 1, 2,
  • 1,
  • 1 and
  • 1
Contributed equally
Journal of Medical Case Reports201913:83

https://doi.org/10.1186/s13256-019-1999-6

  • Received: 25 April 2018
  • Accepted: 28 January 2019
  • Published:
Open Peer Review reports

Abstract

Background

Although liver resection is still the best treatment for primary or metastatic hepatic lesions, a conventional surgical approach may be challenging in patients with a history of previous abdominal surgery. We present a case of a 58-year-old white man with paracaval, subdiaphragmatic, recurrent hepatocellular carcinoma; he had a history of multiple abdominal surgeries.

Methods

In select patients, percutaneous ultrasound-guided thermal ablation is a valid non-surgical alternative due to its safety, efficacy, and good tolerability. Hepatic lesions located in the posterosuperior segments, however, can be difficult to reach via a percutaneous approach.

Result

For these cases, one-lung left-sided ventilation may be particularly helpful in blocking the right hemidiaphragm and improving the acoustic window to the liver.

Conclusion

We present a case of paracaval, subdiaphragmatic, recurrent hepatocellular carcinoma in which the tumor was only reachable after one-lung left-sided ventilation that was successfully treated by percutaneous ultrasound-guided microwave ablation.

Keywords

  • Minimally invasive surgery
  • Hepatocellular carcinoma treatment
  • MW ablation
  • One-lung ventilation
  • Bridge to liver transplantation

Introduction

Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide, and liver transplantation (LT) is considered the preferred treatment of choice. However, when LT is not feasible (due to organ shortage, liver waiting list, and/or patient performance status), liver resection or locoregional treatments are the most frequent alternatives. Even if open resection has been considered the most curative strategy, in the last two decades, the efficacy of local ablation techniques has improved, especially in selected patients, showing no difference in terms of overall survival between liver resection and minimally invasive treatment [14].

Ultrasound (US)-guided microwave ablation (MWA) can be performed through a percutaneous, laparoscopic, transthoracic, or laparotomic approach. In very few select cases, MWA can also be used in an emergency setting, as reported recently in the literature [5]. When a laparotomic or laparoscopic approach is not feasible, a percutaneous approach represents a valid, safe, and effective alternative. However, every approach has pros and cons in relation to the clinical situation. Despite the well-known advantages of minimally invasive approaches, small and deep tumors in the posterosuperior areas of the liver, located just under the diaphragm, may not be easily achieved by a US-guided percutaneous approach [6].

Case presentation

In August 2017, a 58-year-old white man was referred to our center of Hepatobiliary Surgery and Liver Transplantation at the Policlinic Hospital of Padua for paracaval, subdiaphragmatic recurrent HCC in the absence of underlying liver disease. He had a history of multiple abdominal surgeries: in August 2015, a laparotomic right hepatectomy for HCC (with negative oncological margins, R0); in April 2016, excision of cutaneous HCC metastases; and in January 2017, a local intrahepatic recurrence of HCC occurred, treated with liver and diaphragm en bloc resection with right diaphragmatic patch located near the resection margin. Both resections were performed in another hospital via a J-shaped incision.

During the follow-up, a thoracoabdominal triple-phase computed tomography (CT) scan showed a HCC nodule of 18 × 14 mm located immediately upstream of the confluence of the middle hepatic vein with the inferior vena cava (Fig. 1a, b). Abdominal US evaluation did not clearly detect the hepatic lesion due to lung and bowel interposition. He was asymptomatic, had a normal level of alpha-fetoprotein (AFP), negative hepatitis viral markers, and normal liver function: Child–Pugh A5 and Model for End-Stage Liver Disease (MELD) 6. His body mass index (BMI) was 24.
Fig. 1
Fig. 1

a and b Computed tomography abdominal scan, hepatocellular carcinoma nodule of 18 × 14 mm near the confluence of the middle hepatic vein and the inferior vena cava (arterial and venous phase). c and d Three-month follow-up computed tomography abdominal scan, complete necrosis of the nodule (arterial and venous phase). The area of the nodule pre-procedure and postprocedure is indicated by an arrow

Methods

Considering the previous multiple abdominal surgeries, initially we decided to approach the lesion thoracoscopically. This surgical procedure was performed in October 2017. Before surgery, spirometry and carbon monoxide pulmonary diffusing capacity were evaluated. A left double lumen tube was placed after induction of general anesthesia. Our patient was placed in a left lateral decubitus and mild anti-Trendelenburg position. During one-lung left-sided protective ventilation (tidal volume, 500 ml; respiratory rate, 12/minute; positive end-expiratory pressure, 6 cmH2O; fraction of inspired oxygen, 35%), the gas exchange did not differ significantly compared to that of baseline: partial pressure of oxygen in arterial blood (PaO2) 114 mmHg versus 135 mmHg; oxygen saturation (SatO2) 98.2% versus 98.4%; partial pressure of carbon dioxide in arterial blood (PaCO2) 38 mmHg versus 44 mmHg. The hepatic dome was scanned with a 3.5 MHz curved-array US probe through the ninth and tenth intercostal space along the right anterior axillary line. The expected hypoechogenic lesion was easily found because of the immobilization of the right-side of the diaphragm. In consideration of the better visualization of the HCC due to the lung exclusion, we changed to an intercostal percutaneous approach instead of a thoracoscopic method.

An internally cooled MWA antenna (AMICA generator and AMICA probe 14G, 27 mm; HS Hospital Service SpA, Aprilia, Italy; Food & Drug Administration, FDA, and Conformité Européenne, CE, approved) was inserted just above the costal margin into the lesion, with the shortest and safest needle trajectory, under real-time US guidance (Fig. 2). The probe was powered at 40 Watts for 4 minutes until the complete ablation of the lesion, including the desired safety margin.
Fig. 2
Fig. 2

Microwave ablation needle insertion in the hepatocellular carcinoma liver nodule under ultrasound guidance. A antenna microwave, D diaphragm, IVC inferior vena cava, LHV left hepatic vein, RV right ventricle, T cancer

Our patient showed stable respiratory and cardiovascular parameters during the procedure. At the end, he was quickly awakened and the double lumen tube gently removed without complications after re-expansion of his right lung. Blood count, transaminases, abdominal US examination, and chest X-ray were performed at 5 hours from the procedure to exclude early ablative complications, such as pneumothorax and unilateral pleural effusion. The postoperative period was uneventful and our patient was discharged on the same day of the procedure [7].

Results

To evaluate the efficacy of the ablative technique, CT scans of his abdomen with contrast in arterial and portal phases were performed at 1 and 3 months post-operation. We analyzed the effect of the ablation treatment using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria [8]. The imaging was evaluated by three different radiologists. Safety was evaluated considering intraoperative and postoperative mortality and morbidity (30 days after surgery).

No complication occurred during or after surgery, and our patient was discharged on the day of the operation. No contrast enhancement in the target region was appreciable at the follow-up CT scans performed after 1 and 3 months, corresponding to a complete response according to mRECIST classification (Fig. 1c, d). His AFP level was also normal. Thus far, after 4 months of follow-up, no late complications have occurred.

Conclusion

Percutaneous US-guided ablation during one-lung left-sided ventilation has proven to be clinically feasible and safe, particularly as an effective therapy for deep subdiaphragmatic hepatic lesions that are otherwise difficult to access.

Usually the right lung covers a significant portion of the upper abdomen, limiting the window of posterosuperior hepatic lesions to an intercostal percutaneous approach. To date, few reports have described percutaneous ablation with local anesthesia for HCC located in the hepatic dome close to the diaphragm [9, 10]. Even under US-guided or CT-guided ablation, especially in the presence of ascites or pleural effusion, or when the artificial type of them is locally infused to create a buffer zone, the risk of pneumothorax, burn injury, and infection remains still high [1113].

One-lung left-sided ventilation reduces contralateral hemidiaphragm motion and improves the US window allowing easy access to the hepatic dome. General anesthesia, immobilization of the liver and real-time US permit safe ablation without risk of burn lesions to adjacent organs due to a patient’s response to pain. These features are especially helpful in cases of patient obesity, which is usually considered a contraindication to a percutaneous approach.

In patients with history of multiple prior laparotomies, in which a laparoscopic approach may be difficult to perform, this technique represents a valid alternative to a subsequent difficult and risky laparotomy or a more invasive transthoracic ablation [1416].

The procedure is tolerable and acceptable to patients, as indicated by minimal postoperative pain and short recovery time. In comparison to the more invasive approaches it also has a lower cost and complication rate [17].

We believe the encouraging results of this case justify further investigation and clinical use of one-lung left-sided ventilation to achieve percutaneous ablation of hepatic dome tumors.

Notes

Abbreviations

AFP: 

Alpha-fetoprotein

BMI: 

Body mass index

CE: 

Conformité Européenne

CT: 

Computed tomography

FDA: 

Food & Drug Administration

HCC: 

Hepatocellular carcinoma

LT: 

Liver transplantation

MELD: 

Model for End-Stage Liver Disease

mRECIST: 

Modified Response Evaluation Criteria in Solid Tumors

MWA: 

Microwave ablation

PaCO2

Partial pressure of carbon dioxide in arterial blood

PaO2

Partial pressure of oxygen in arterial blood

SatO2

Oxygen saturation

US: 

Ultrasound

Declarations

Acknowledgements

We thank the Director of Radiology of the Veneto Oncological Institute, Camillo Aliberti and his staff, and the Director of Radiology at Padova University, Diego Miotto and his staff, for their review of the images.

Funding

No grant has supported this work.

Availability of data and materials

The CT scan is saved in the e-health system of our hospital with the clinical history reported in the case report and is accessible any time if requested by the editor.

Authors’ contributions

Study conception and design: FD, SS. Acquisition of data: SS, MF, CDR, MDB. Analysis and interpretation of data: FD, UC. Drafting of manuscript: SS, MF, CDR, MDB. Critical revision: FD, UC. Performed surgery: UC, FD. All authors have agreed to the content of this manuscript and agree with its submission to the Journal.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova, Via Giustiniani 2, 35128 Padova, Italy
(2)
Department of Surgery, Division of Transplantation and Immunology, Yale University, New Haven, CT, USA

References

  1. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Ann Surg. 2006;243(3):321–8. https://doi.org/10.1097/01.sla.0000201480.65519.b8.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Forner A, Llovet JM, Bruix J. Hepatocellular Carcinoma. Lancet. 2012;379(9822):1245–55. https://doi.org/10.1016/s0140-6736(11)61347-0.View ArticlePubMedGoogle Scholar
  3. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival Comparison between Surgical Resection and Radiofrequency Ablation for Patients in BCLC Very Early/Early Stage Hepatocellular Carcinoma. J Hepatol. 2012;56(2):412–8. https://doi.org/10.1016/j.jhep.2011.05.020.View ArticlePubMedGoogle Scholar
  4. Xu Y, Shen Q, Wang N, Wu PP, Huang B, Kuang M, et al. Microwave Ablation Is as Effective as Radiofrequency Ablation for Very-Early-Stage Hepatocellular Carcinoma. Chin J Cancer. 2017;36(1) https://doi.org/10.1186/s40880-017-0183-x.
  5. Bertacco A, D’Amico F, Romano M, Finotti M, Vitale A, Cillo U. Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report. J Med Case Rep. 2017;11(1):54. https://doi.org/10.1186/s13256-017-1199-1.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Shibata T, Iimuro Y, Yamamoto Y, Ikai I, Itoh K, Maetani Y, et al. CT-Guided Transthoracic Percutaneous Ethanol Injection for Hepatocellular Carcinoma Not Detectable with US. Radiology. 2002;223(1):115–20. https://doi.org/10.1148/radiol.2231010862.View ArticlePubMedGoogle Scholar
  7. Ahn Y, Woods J, Connor S. A Systematic Review of Interventions to Facilitate Ambulatory Laparoscopic Cholecystectomy. HPB. 2011;13(10):677–86. https://doi.org/10.1111/j.1477-2574.2011.00371.x.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.View ArticlePubMedGoogle Scholar
  9. Kondo Y, Yoshida H, Tateishi R, Shiina S, Kawabe T, Omata M. Percutaneous Radiofrequency Ablation of Liver Cancer in the Hepatic Dome Using the Intrapleural Fluid Infusion Technique. Br J Surg. 2008;95(8):996–1004. https://doi.org/10.1002/bjs.6058.View ArticlePubMedGoogle Scholar
  10. Toyoda M, Kakizaki S, Horiuchi K, Katakai K, Sohara N, Sato K, et al. Computed Tomography-Guided Transpulmonary Radiofrequency Ablation for Hepatocellular Carcinoma Located in Hepatic Dome. World J Gastroenterol. 2006;12(4):608. https://doi.org/10.3748/wjg.v12.i4.608.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Inoue T, et al. Percutaneous Ultrasound-Guided Radiofrequency Ablation with Artificial Pleural Effusion for Hepatocellular Carcinoma in the Hepatic Dome. J Gastroenterol. 2003;38(11):1066–70. https://doi.org/10.1007/s00535-003-1197-5.View ArticlePubMedGoogle Scholar
  12. Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, et al. Complications of Radiofrequency Ablation for Hepatocellular Carcinoma in a Multicenter Study: An Analysis of 16346 Treated Nodules in 13283 Patients. Hepatol Res. 2012;42(11):1058–64. https://doi.org/10.1111/j.1872-034x.2012.01025.x.View ArticlePubMedGoogle Scholar
  13. Ding H, Su M, Zhu C, Wang L, Zheng Q, Wan Y. CT-Guided versus Laparoscopic Radiofrequency Ablation in Recurrent Small Hepatocellular Carcinoma against the Diaphragmatic Dome. Sci Rep. 2017;7:44583. https://doi.org/10.1038/srep44583.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Ishikawa T, Kohno T, Shibayama T, Fukushima Y, Obi S, Teratani T, et al. Thoracoscopic Thermal Ablation Therapy for Hepatocellular Carcinoma Located Beneath the Diaphragm. Endoscopy. 2001;33(8):697–702. https://doi.org/10.1055/s-2001-16216.View ArticlePubMedGoogle Scholar
  15. Kambadakone A, Baliyan V, Kordbacheh H, Uppot RN, Thabet A, Gervais DA, et al. Imaging Guided Percutaneous Interventions in Hepatic Dome Lesions: Tips and Tricks. World J Hepatol. 2017;9(19):840. https://doi.org/10.4254/wjh.v9.i19.840.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Kang CM, Ko HK, Song SY, Kim KS, Choi JS, Lee WJ, et al. Dual-Scope Guided (Simultaneous Thoraco-Laparoscopic) Transthoracic Transdiaphragmatic Intraoperative Radiofrequency Ablation for Hepatocellular Carcinoma Located beneath the Diaphragm. Surg Endosc. 2007;22(2):541. https://doi.org/10.1007/s00464-007-9410-x.View ArticlePubMedGoogle Scholar
  17. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, et al. Early and Late Complications After Radiofrequency Ablation of Malignant Liver Tumors in 608 Patients. Ann Surg. 2004;239(4):450–8. https://doi.org/10.1097/01.sla.0000118373.31781.f2.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement